Immune booster drug shows promise for brain tumor patients
NCT ID NCT03687957
First seen Jan 09, 2026 · Last updated Jun 18, 2026 · Updated 24 times
Summary
This study tests a drug called rhIL-7-hyFc in people with high-grade gliomas (a type of brain tumor) whose immune cell counts are low after standard radiation and chemotherapy. The goal is to see if the drug can safely increase lymphocyte levels, which help fight infections. About 42 participants will receive either the drug or a placebo.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GLIOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Washington University School of Medicine
St Louis, Missouri, 63110, United States
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.